Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Herbalife Nutrition Ltd (HLF) vs Novartis AG (NVS) Price & Performance

Herbalife Nutrition LtdTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Herbalife Nutrition Ltd vs Novartis AG — how do they compare? Herbalife Nutrition Ltd trades at $11.77 (market cap $1.23B), while Novartis AG trades at $152.37 (market cap $295.37B). The key difference: Novartis AG is far larger — about 240.1× Herbalife Nutrition Ltd's market cap, and Novartis AG pays a 3.07% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals.

HLFNVS
Market Cap
$1.23B$295.37B
Sector
Consumer StaplesHealth
52-Week High
$19.96$168.62
52-Week Low
$7.75$119.31
Enterprise Value
$3.06B$336.69B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Herbalife Nutrition Ltd

HLF trades at $11.71, up 1.65% on the day, with a bearish technical signal from moving averages. The company shows mixed earnings, missing Q2 2026 EPS estimates but achieving four consecutive quarters of sales growth. Valuation ratios appear attractive with a P/E of 7.53 and P/S of 0.24, though negative shareholder equity and high debt levels present financial risks. Recent news includes a planned CFO transition and inclusion in TIME's America's Best Companies 2026 list.

The outlook for HLF balances low valuation against operational and financial challenges. Investment opportunity lies in potential margin improvement and debt reduction, but risks include earnings volatility, high leverage, and competitive pressures in the nutrition space. Analyst sentiment is cautiously optimistic with a majority buy rating.

Novartis AG

Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.

The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Herbalife Nutrition Ltd

Herbalife Nutrition Ltd is an international nutrition company.

Read more on HLF

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS